Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK pathways play important roles in cellular differentiation and survival. MAPKs are serine/threonine protein kinases that can phoshorylate both cytoplasmic and nuclear targets. MAPKs are associated with aberrant, chronic or hyper-phosphorylation found in cancerous and other diseased tissues. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions.

Public Health Relevance

Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM090387-01
Application #
7800495
Study Section
Special Emphasis Panel (ZRG1-IMST-G (11))
Program Officer
Fabian, Miles
Project Start
2010-03-01
Project End
2011-08-31
Budget Start
2010-03-01
Budget End
2011-08-31
Support Year
1
Fiscal Year
2010
Total Cost
$98,917
Indirect Cost
Name
Caldera Pharmaceuticals, Inc.
Department
Type
DUNS #
147452275
City
Los Alamos
State
NM
Country
United States
Zip Code
87544